Key Facts
• On September 10, 2025, Sawai Pharmaceutical and Nichi-Iko announced a collaboration.
• The partnership focuses on improving production efficiency for generic drugs.
• Plans include consolidating manufacturing facilities and integrating 30 product lines.
• Implementation is set to begin in 2026.
• Both companies currently produce overlapping product lines.
• Future strategy involves one company manufacturing specific products and supplying the other.
• Since 2020, the generic drug industry has faced supply shortages due to corporate scandals.
• The market has expanded but struggles with low production efficiency due to “small-volume, multi-product” operations.
• Increased quality control demands have added to operational challenges.
Summary
Sawai Pharmaceutical and Nichi-Iko have joined forces to address supply stability in the growing generic drug market. Announced on September 10, 2025, the collaboration aims to enhance production efficiency by consolidating manufacturing facilities and integrating 30 product lines, with implementation starting in 2026. The companies plan to streamline operations by assigning specific product manufacturing to one company while supplying the other. This move comes as the industry grapples with supply shortages caused by corporate scandals since 2020, alongside challenges from low production efficiency and increased quality control demands. The partnership seeks to ensure a more reliable supply chain for generic drugs.
